Neuren’s Pitt Hopkins’ study recruitment page is highlighting that recruitment is closing next month.
Phelan McDermid enrolment completion was announced on June 30, with results due in December. This suggests that we might have results in Pitt Hopkins by April next year.
The Angelman Syndrome study, the only one recruiting in Australia (Sydney, Melbourne, Brisbane), is still seeking participants. Unlike Pitt Hopkins, this study has competition, with Biogen also recruiting in Sydney and Ultragenyx recruiting in Brisbane. Biogen’s Phase 1/2 trial is expected to run until the end of 2024 and Ultragenyx’s Phase 1/2 trial has expected completion in December 2025.
https://pthsstudy.com/
Pitt Hopkins
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$20.25 |
Change
0.430(2.17%) |
Mkt cap ! $2.585B | |||
| Open | High | Low | Value | Volume |
| $19.89 | $20.39 | $19.77 | $5.715M | 283.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 355 | $20.22 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $20.29 | 302 | 1 |
View Market Depth
| Last trade - 16.10pm 07/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$20.22 |
Change
0.430 ( 2.40 %) |
||||
| Open | High | Low | Volume | ||
| $19.86 | $20.40 | $19.77 | 85257 | ||
| Last updated 15.59pm 07/05/2024 ? | |||||
| NEU (ASX) Chart |